After A Brief Pause, Injectables Cash Cow Agila Is Back Into Production; Pfizer Expects Shipping To Commence Soon
This article was originally published in PharmAsia News
Executive Summary
Agila, as its name suggests, was agile in correcting deficiencies outlined in an FDA 483 last month and is back on track to supply global customers like Pfizer, GSK and Eli Lilly. But Mylan’s planned buyout of Agila, Strides Arcolab’s cash cow, has hit a snag and been put on hold by India’s finance ministry.